AI Health Insights

Genomic testing is expanding rapidly from constrained clinical use to direct-to-consumer longevity tools, exposing both access barriers and new...

Leading efforts combine data-centric biology with new collaborations and tools.

• Daphne Koller at insitro stresses scarce data, causality needs, and...

High failure rates define drug development: most lead compounds fail before preclinical testing, few reach clinical trials, and only one in ten...

• Pathos AI closed $2.3B cancer deals and targets $3B valuation, using its Foundry platform and 7.3M patient records to design smarter trials
• AI...

GenAI companions like Meela and ElliQ help combat loneliness by offering conversation, reminders, and cognitive exercises.

• Key benefits: Reduce...

A novel deep learning pipeline using genomic multi-level mixture of experts detects HPV integration sites in tumor genomes. This technical advance demonstrates AI's growing role in precision oncology.

Deep learning models trained on consensus labels from four existing methods reach over 74% accuracy on independent single-cell RNA sequencing datasets...

The first AI-originated molecules from regional platforms now carry real clinical data, moving the field past pure hypothesis.

• Insilico Medicine...

Trust in AI evaluations is often assumed rather than demonstrated, as benchmarks can measure the wrong constructs, prove brittle on new data, or...

• Gray market peptides are shifting from research labs into consumer supplements, blurring drug-supplement lines and prompting calls for tighter...

AI is shifting from easing administrative loads to aiding clinical decisions, with tools like OpenEvidence delivering source-backed medical answers to...

Cleveland Clinic and IBM researchers unveiled Q-CHIPP, the first quantum machine learning framework to predict antigen presentation and immunotherapy...

A LightGBM model trained on 8 routine blood parameters distinguished myelodysplastic syndromes (MDS) from aplastic anemia with an external-validation...

High-quality biological data and wet-lab validation remain the true bottlenecks in AI drug discovery, not model sophistication.

• GSK-Relation deal...

Growing capital and academic ties are expanding whole-genome and single-cell tools for cancer.

• Nabsys partners with Indiana University to test...

A major FDA database analysis found Wegovy tied to nearly five times higher odds of optic nerve injury (NAION) than Ozempic, with men showing over 116...

Interpretable AI reveals molecular features driving drug predictions.

• Multi-omics deep learning predicts metastasis and biomarkers.
• Trend points...

• Market projected to jump from USD 1.6 billion in 2026 to USD 42.8 billion by 2035 at 44.1% CAGR
• North America dominates with 55.2% share, backed...

Standardized benchmarks like Insilico's DDD BaaS now test AI models on real-world drug discovery tasks using decontaminated data, moving beyond...

An honors thesis presents an interpretable ML framework using 146 plasma analytes to detect Alzheimer's stages non-invasively.

• Strong performance:...